Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America. But Heard on ...

For example, Brittany found that drugs being developed by Generate were modified versions of existing antibodies, and that ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hims and Hers has been slammed for its Super Bowl commercial that admonished Americans for being obese and shamed the healthcare industry - then promoted its own weight loss drugs.  The 60-second ...